Comparison of three dissolution apparatuses for testing calcium phosphate pellets used as ibuprofen delivery systems

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 597-605

  Chevalier, Emilie ^a   Viana, Marylène ^a   Artaud, Aymeric ^b   Chomette, Lisette ^c   Haddouchi, Samir ^b   Devidts, Gille ^c   Chulia, Dominique ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b SPS Pharma Services   (France)

^c Varian SA   (France)

Author keywords

Calcium phosphate pellets; Flow through cell; Ibuprofen delivery system; invitro drug release; Paddle apparatus; Reciprocating cylinder

Indexed keywords

CALCIUM PHOSPHATE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALYTIC METHOD; APPARATUS; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG GRANULATION; DRUG PELLET; DRUG SOLUBILITY; EQUIPMENT DESIGN; INTERMETHOD COMPARISON; SUSTAINED RELEASE PREPARATION; CHEMISTRY; DRUG DELIVERY SYSTEM; INSTRUMENTATION; PHARMACEUTICS; SOLUBILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM PHOSPHATES; DRUG DELIVERY SYSTEMS; IBUPROFEN; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 67549091738     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9252-z     Document Type: Article

References (59)

1. Pillay V, Fassihi R. Evaluation and comparison of dissolution data derived from different modified release dosage forms: An alternative method. J Contr Rel. 1998;55:45-55.
2. Missaghi S, Fassihi R. Release characterization of dimehydrinate from an eroding and swelling matrix: Selection of appropriate dissolution apparatus. Int J Pharm. 2005;293:35-42.
3. Joshi A, Pund S, Nivsarkar M, Vasu K, Shishoo C. Dissolution test for site-specific release isomiazid pellets in USP apparatus 3 (reciprocating cylinder): Optimization using response surface methodology. Eur J Pharm Biopharm. 2008;69:769-75.
4. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS Guidelines to dissolution in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4:1-10.
5. Mattok GL, McGilveray IJ, Hossie RD. Technical problems of the USP/NF dissolution test. J Pham Sci. 1971;61:460-2.
6. Smolen VF, Weigand WA. Optimally predictive in vitro drug dissolution testing for in vivo bioavailability. J Pharm Sci. 1976;65:1718-24.
7. Nasir SS, Wilken Jr LO, Nasir SM. New in vitro dissolution test apparatus. J Pharm Sci. 1978;68:177-81.
8. Roseman TJ, Derr GR, Nelson KG, Lieberman BL, Butler SS. Continuous flow bead-bed dissolution apparatus for suppositories. J Pharm Sci. 1980;70:646-51.
9. Brossard C, Lefort des Ylouses D, Duchúne D, Puisieux F, Carstensen JT. Dissolution of a soluble drug substance from vinyl polymer matrices. J Pharm Sci. 1982;72:162-9.
10. Aiache JM, Islasse M, Beyssac E, Aiache S, Renoux R, Kantelip JP. Kinetics of indomethacin release from suppositories. In vitro - in vivo correlation. Int J Pharm. 1987;39:235-42.
11. Aiache JM. French and/or European perspectives on biopharmaceutical characterization of drug dosage forms. J Pharm Biomed Anal. 1990;8:499-506.
12. Mehta AC. Dissolution testing of tablet and capsule dosage forms. J Clin Pharm Ther. 1993;18:415-20.
13. Jorgensen E, Bhagwat D. Development of dissolution tests for oral extended-release products. PSTT 1998;1:128-35.
14. Beyssac E, Lavigne J. Dissolution study of active pharmaceutical ingredients using the flow through apparatus USP 4. Dissolution Technologies 2005;12:23-5.
15. Graffner C. Regulatory aspects of drug dissolution from a European perspective. Eur J Pharm Sci. 2006;29:288-93.
16. US Department of Health and Human Services, Food and Drug Administration, Center of Drug Evaluation and Research (CDER). Guidance for industry: Dissolution testing of immediate release solid dosage forms. Rockville: FDA; 1997.
17. US Department of Health and Human Services, Food and Drug Administration, Center of Drug Evaluation and Research (CDER). Guidance for industry: Extended releaseDoral dosage forms: development, evaluation and application of in vitro/in vivo correlations. Rockville: FDA; 1997.
18. International Conference of Harmonization, ICH Q8 Pharmaceutical Development, www.ich.org; 2 September 2008.
19. Council of Europe. European Pharmacopoeia. 6th ed. Strasbourg: Council of Europe; 2006.
20. The United States Pharmacopoeia 29th ed, United States Pharmacopoeial Convention, Rockville, 2006.
21. Maggio RM, Castellano PM, Kaufman TS. A new principle component analysis-based approach for testing "similarity" of drug dissolution profiles. Eur J Pharm Sci. 2008;34:66-77.
22. Dürig T, Fassihi R. Evaluation of floating and sticking extended release delivery systems: An unconventional dissolution test. J Contr Release 2000;67:37-44.
23. Kukura J, Baxter JL, Muzzio FJ. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions. Int J Pharm. 2004;279:9-17.
24. De Groot K. Bioceramics consisting of calcium phosphate salts. Biomaterials 1980;1:47-50.
25. LeGeros RZ. Calcium phosphate materials in restorative dentistry: A review. Adv Dent Res. 1988;2:164-80.
26. Daculsi G, LeGeros RZ, Nery E, Lynch K, Kerebel B. Transformation of biphasic calcium phosphate ceramics in vivo: Ultrastructural and physicochemical characterization. J Biomed Mat Res. 1989;23:883-94.
27. Passuti N, Daculsi G, Martin S, Basle M, Roher S. In Heimke G, Soltesz U, Lee AJC (eds). Macroporous calcium phosphate ceramics for long bone surgery in human and dogs - Clinical and histological studies. Clinical Implants Materials. Advances in Biomaterials. BV, Amsterdam: Elsevier Sciences Publishers, 1990, pp. 255-258.
28. Vallet-Regi M, Gonzalez-Calbet JM. Calcium phosphates as substitution of bone tissues. Prog Solid State Chem. 2004;32:1-31.
29. Daculsi G, LeGeros RZ, Heughebaert M, Barbieux I. Formation of carbonate-apatite crystals after implantation of calcium phosphate ceramics. Calcif Tissue Int. 1990;46:20-7.
30. LeGeros RZ, Daculsi G, Orly I, Gregoire M, Heughebaert M, Gineste M, Kijkowska R. In Ducheyne, Kokubo, Van Blitterswijk (eds). Formation of carbonate apatite on calcium phosphate materials: Dissolution/ precipitation processes. Bone-bonding. Reed Healthcare Communications, 1992, pp. 201-212.
31. Arcos D, Ragel CV, Vallet-Regi M. Bioactivity in glass/PMMA composites used as drug delivery system. Biomaterials 2001;22:701-8.
32. Meseguer-Olmo L, Ros-Nicolas MJ, Clavel-Sainz M, Vicente-Ortega V, Alcaraz-Banos M, Lax-Perez A, Arcos D, Ragel CV, Vallet-Regi M. Biocompatibility and in vivo gentamicin release from bioactive sol-gel glass implants. J Biomed Mater Res Part A 2002;61:458-65.
33. Ginebra MP, Traykova T, Planell JA. Calcium phosphate cements as drug delivery systems: A review. J Control Release 2006;113:102-10.
34. Balcik C, Tokdemir T, Senköylü A, Koc N, Timucin M, Akin S, Korkusuz P, Korusuz F. Early weight bearing of porous HA/TCP (60/40) ceramics in vivo: A longitudinal study in a segmental bone defect model of rabbit. Acta Biomaterialia 2007;3:985-96.
35. Corry D, Moran J. Assessment of acrylic bone cement as a local delivery vehicle for the application of non-steroidal anti-inflammatory drugs. Biomaterials 1998;19:1295-301.
36. Mendez JA, Fernandez M, Gonzalez-Corchon A, Salvado M, Collia F, De Pedro JA, Levenfeld BL, Lopez-Bravo A, Vazquez B, San Roman J. Injectable self-curing bioactive acrylic-glass composites charged with specific anti-inflammatory/analgesic agent. Biomaterials 2004;25:2381-92.
37. Gonzalez-Corchon MA, Salvado M, De la Torre BJ, Collia F, De Pedro JA, Vazquez B, San Roman J. Injectable and self-curing composites of acrylic/ bioactive glass and drug systems. A histomorphometric analysis of the behaviour in rabbits. Biomaterials 2006;27:1778-87.
38. Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int. 2007;46:7548-58.
39. Detsch R, Mayr H, Ziegler G. Formation of osteoclast-like cells on HA and TCP ceramics. Acta Biomaterialia 2008;4:139-48.
40. Guicheux J, Grimandi G, Trécant M, Faivre A, Takahashi S, Daculsi G. Apatite as carrier for growth hormone: In vitro characterization of loading and release. J Biomed Mater Res. 1997;34:165-70.
41. Pillay V, Fassihi R. Unconventional dissolution methodologies. J Pharm Sci. 1999;88:843-51.
42. Krajewski A, Ravaglioli A, Roncari E, Pinasco P. Porous ceramic bodies for drug delivery. J Mater Sci Mater Med. 2000;12:763-71.
43. Sunder M, Babu NR, Victor SP, Kumar KR, Sampath Kumar TS. Biphasic calcium phosphates for antibiotic release. Trends Biomater Artif Organs 2005;18:213-8.
44. Melville AJ, Rodriguez-Lorenzo LM, Forsythe JS. Effects of calcination temperature on the drug delivery behaviour of ibuprofen from hydroxyapatite powders. J Mater Sci Mater Med. 2008;19:1187-95.
45. The United States Pharmacopoeia 22nd ed, United States Pharmacopoeial Convention, Rockville, 1991.
46. Yu LX, Wang JT, Hussain AS. Evaluation of USP Apparatus 3 for dissolution testing of immediate release products. AAPS Pharm Sci. 2002;4:1-5.
47. Chevalier E, Viana M, Pouget C, Chulia D. Influence of process parameters on pellets elaborated in a Mi-Pro high-shear granulator. Pharm Dev Technol. 2007;12:133-44.
48. Chevalier E, Viana M, Pouget C, Cazalbou S, Champion E, Chulia D. In Bioceramics: Properties, Preparations and Application. From porous pellet fabrication to drug loading and release: The case of calcium phosphate matrix loaded with ibuprofen. 2009; in press.
49. Chevalier E, Viana M, Cazalbou S, Chulia D. Validation of a fabrication process of pellets for bone filling and drug delivery. J Drug Deliv Sci Technol. 2008;18(6):438-444.
50. Gibassier D, Sado P, Le Verge R, Devissaguet JP. Test de dissolution et fonction de Weibull. Labo Pharma Pro Tech. 1982;30:250-5.
51. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Tech. 1996;20:64-74.
52. Shah VP, Tsong Y, Sathe P. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15:889-96.
53. Costa P, Sousa Lobo JM. Modelling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-33.
54. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-9.
55. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23:923-31.
56. Kopcha M, Lordi N, Tojo KJ. Evaluation of release from selected thermosoftening vehicles. J Pharm Pharmacol. 1991;43:382-7.
57. Zhou MX, Shoudt D, Calderon G, Feng M. Application of USP Apparatus 7 to in vitro drug release in scopolamine transdermal systems. Dissolution Technol. 2007;14:25-9.
58. Amyot F, Boudy V, Jurski K, Counord JL, Guiffant G, Dufaux J, Chaumeil JC. A new experimental method for the evaluation of the release profiles of drug-loaded microbeads designed for embolisation. ITBM-RBM 2002;23:285-9.
59. Borovac T, Pelage JP, Kasselouri A, Prognon P, Guiffant G, Laurent A. Release of ibuprofen from beads for embolization: In vitro and in vivo studies. J Control Rel. 2006;115:266-74.